论文部分内容阅读
抗纤灵治疗血吸虫病肝纤维化，抗纤Ⅰ方组３３例，抗纤Ⅱ方组３４例及常规治疗对照组１５例。症征疗效分别为９３．９％、９４．１％和６６．７％（Ｐ＜０．０１）。抗纤Ⅰ、Ⅱ方组肝脾Ｂ超七项指标治疗后均有明显改善（Ｐ＜０．０１），肝实质网状结构程度减轻，门静脉内径和壁厚值减小；可降低血清透明质酸和羟脯氨酸含量，提高纤溶酶活性及细胞免疫等水平（Ｐ＜０．０５或Ｐ＜０．０１），达到抑制胶原合成，促进纤维降解之目的。表明抗纤灵抗肝纤维化的机理与其调节免疫功能等有关。
Antifibrosis treatment of schistosomiasis liver fibrosis, anti-fibrosis I group of 33 cases, anti-fibrosis II group of 34 cases and 15 cases of conventional treatment control group. The efficacy of symptoms was 93.9%, 94.1% and 66.7%, respectively (P<0.01). The indexes of liver, spleen and B ultrasound in antifibrosis I and II prescriptions all improved significantly after treatment (P<0.01). The degree of reticular structure of hepatic parenchyma was reduced, and the diameter and wall thickness of portal vein were reduced; serum hyaluronic acid was reduced. The content of acid and hydroxyproline increased the level of plasmin activity and cellular immunity (P<0.05 or P<0.01) to achieve the purpose of inhibiting collagen synthesis and promoting fiber degradation. It shows that the mechanism of anti-fibrosis anti-fibrosis is related to its regulation of immune function.